Optimized lentivirus-derived virus-like particles for efficient delivery of Cas9-based genome editors
Nucleic Acids Research · 20.05.2026 · 54 (10)
DOI: 10.1093/nar/gkag500 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acids Research, online erschienen am 21.05.2026. Verfasst von Boya Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Boston Children's Hospital, Boston MA 02115, United States. Hauptthemen laut MEDLINE: Gene Editing, CRISPR-Cas Systems, Lentivirus, CRISPR-Associated Protein 9. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Gates Foundation, Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
Implementation of therapeutic genome editing requires a potent, versatile, and transient delivery system to enable safe and effective in vivo applications. Here, we report on an optimized virus-like particle (VLP) platform for protein-based delivery of Cas9 ribonucleoproteins and Cas9-derived base editors and prime editors, termed LV-VLP-MA, that enables flexible editor deployment. By systematically engineering a panel of truncated Gag–Cas9 fusion variants, we identify a minimal MA-Cas9 configuration that maximizes editor packaging while effectively preserving efficient particle production and functional delivery. Systematic refinement of VLP production parameters enhances particle yield, supporting robust editing activity across diverse genomic targets. Importantly, systemic administration of LV-VLP-MA mediates efficient in vivo editing of the Pcsk9 locus with functional target suppression, establishing proof-of-concept for therapeutic application. Together, these results define a programmable, modular VLP-based platform that combines potency, flexibility, and transient delivery to expand the scope of in vivo genome engineering for therapeutic development.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Hematology/Oncology, Boston Children's Hospital, Boston MA 02115, United States.
- Department of Pediatrics, Harvard Medical School, Boston MA 02115, United States.
- Department of Pediatric Oncology, Dana-Farber Cancer Institute, Boston MA 02115, United States.
- Harvard Stem Cell Institute, Harvard University, Boston MA 02115, United States.
ORCID-Profile: Boya Liu, David A Williams
Förderung
- Gates Foundation
- Bill and Melinda Gates Foundation
Zitieren
APA
Liu, B., Klatt, D., Harris, C., McGuinness, M., Brendel, C., & Williams, D. A. (2026). Optimized lentivirus-derived virus-like particles for efficient delivery of Cas9-based genome editors. Nucleic Acids Research, 54(10). https://doi.org/10.1093/nar/gkag500
Vancouver
Liu B, Klatt D, Harris C, McGuinness M, Brendel C, Williams DA. Optimized lentivirus-derived virus-like particles for efficient delivery of Cas9-based genome editors. Nucleic Acids Research. 2026;54(10). doi:10.1093/nar/gkag500
BibTeX
@article{Liu2026,
author = {Liu, Boya and Klatt, Denise and Harris, Chad and McGuinness, Meaghan and Brendel, Christian and Williams, David A},
title = {Optimized lentivirus-derived virus-like particles for efficient delivery of Cas9-based genome editors},
journal = {Nucleic Acids Research},
year = {2026},
volume = {54},
number = {10},
doi = {10.1093/nar/gkag500}
}
EUVIMED